Results 121 to 130 of about 62,912 (312)

Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study

American Journal of Gastroenterology
INTRODUCTION: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the risk of postoperative complications of tofacitinib exposure before colectomy in comparison with biologics ...
G. Dragoni, T. Innocenti, A. Amiot, F. Castiglione, L. Melotti, S. Festa, E. Savarino, M. Truyens, K. Argyriou, D. Noviello, Tamás Molnár, V. Bouillon, C. Bezzio, P. Eder, S. Fernandes, A. Kagramanova, A. Armuzzi, R. Oliveira, A. Viola, D. Ribaldone, I. Drygiannakis, C. Viganò, F. Calella, A. G. Gravina, D. Pugliese, M. Chaparro, P. Ellul, S. Vieujean, M. Milla, F. Caprioli   +29 more
semanticscholar   +1 more source

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

Clinical Pharmacology &Therapeutics, EarlyView.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko, Philip C. M. Au, Michael Chun‐Yuan Cheng, Ching‐Lung Cheung, Ahhyung Choi, Miyuki Hsing‐Chun Hsieh, Han Eol Jeong, Edward Chia‐Cheng Lai, Brian Meng‐Hsun Li, Kenneth K. C. Man, Jeremy A. Rassen, Daniel Hsiang‐Te Tsai, Shirley V. Wang, Ian C. K. Wong, Ju‐Young Shin, Sohee Park   +15 more
wiley   +1 more source

Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study

Intestinal Research
Background/Aims The efficacy and safety of tofacitinib for the treatment of refractory ulcerative colitis (UC) has been demonstrated in clinical trials. Although, a series of reports with real-world evidence of its short-term efficacy and safety profiles
H. Shimizu, Yuko Aonuma, Shuji Hibiya, Ami Kawamoto, K. Takenaka, T. Fujii, E. Saito, M. Nagahori, Kazuo Ohtsuka, R. Okamoto   +9 more
semanticscholar   +1 more source

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source

Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis [PDF]

, 2022
Bram Verstockt, Valery Volk, Charlot Jaeckel, Dahham Alsoud, João Sabino, Susanna Nikolaus, An Outtier, Nicole Krönke, Friedrich Feuerhake, Gert De Hertogh, Philip Rosenstiel, Séverine Vermeire, Stefan Schreiber, Marc Ferrante, Konrad Aden   +14 more
openalex   +1 more source

Perioperative utilization of JAK inhibitors in Perianal Fistulizing Crohn's disease

JPGN Reports, EarlyView.
Abstract With the recent approval of small molecule drugs such as upadacitinib in adult inflammatory bowel disease (IBD), their utilization is becoming more common; however, there is limited data on perioperative risks or optimal timing of cessation and resumption to mitigate flares. Current recommendations suggest holding these medications for 14 days
Alexander Lyons, Lindsey Lawrence, Samantha Saul   +2 more
wiley   +1 more source

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Arthritis Research & Therapy
Background Data on treatment switching directly from tumor necrosis factor inhibitors to tofacitinib in psoriatic arthritis (PsA) are limited. This post hoc analysis assessed efficacy and safety outcomes in patients with PsA who directly switched to ...
Dafna D. Gladman, Peter Nash, Philip J. Mease, Oliver FitzGerald, Stephanie Duench, Mary Jane Cadatal, Karim R. Masri   +6 more
doaj   +1 more source

Ruxolitinib and vedolizumab salvage therapy in the setting of cytomegalovirus colitis for a patient with newly diagnosed very early onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Acute severe ulcerative colitis increases the risk for cytomegalovirus (CMV) infection, particularly with the use of immunocompromising medications. We report a case of a 4‐year‐old with newly diagnosed very early onset inflammatory bowel disease presenting with acute severe colitis refractory to both corticosteroids and infliximab, whose ...
Alison Laxer, Morris Edelman, Julie Gallagher, Benjamin Sahn   +3 more
wiley   +1 more source

The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study

Arthritis Research & Therapy
Background A consistent connection has been increasingly reported between rheumatoid arthritis (RA), insulin resistance (IR), and type 2 diabetes (T2D). The β-cell apoptosis induced by pro-inflammatory cytokines, which could be exaggerated in the context
C. Di Muzio, I. Di Cola, A. Shariat Panahi, Francesco Ursini, A. Iagnocco, Roberto Giacomelli, Paola Cipriani, P. Ruscitti   +7 more
semanticscholar   +1 more source

Impact of tofacitinib on patient-reported outcomes in patients with psoriatic arthritis. Data from the real clinical practice

, 2022
L. D. Vorobyeva, Т. В. Коротаева, Е. Yu. Loginova, Yu. L. Kоrsakova, Е. Е. Gubar, Е. Л. Насонов   +5 more
openalex   +2 more sources